Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Oncotarget | 2016-10-18 | PMID 27611952
Darb-Esfahani Silvia, Denkert Carsten, Stenzinger Albrecht and 20 more
